Plasma Exchange Therapy in Postural Tachycardia Syndrome: A Novel Long-Term Approach? - 21/04/20

Doi : 10.1016/j.amjmed.2019.10.016

Rachel Wells, MBBS ^a,^b, Pravin Hissaria, MBBS, MD, DM ^c,^d, Adrian D. Elliott, PhD ^a, Prashanthan Sanders, MBBS, PhD ^a,^e, Amanda Page, PhD ^b,^f, Mathias Baumert, PhD ^g, Dennis H. Lau, MBBS, PhD ^a,^e,^⁎
^a Centre for Heart Rhythm Disorders, Royal Adelaide Hospital, Adelaide, South Australia, Australia
^b Department of Medicine, Royal Adelaide Hospital, Adelaide, South Australia, Australia
^c Department of Immunology, Royal Adelaide Hospital, Adelaide, South Australia, Australia
^d SA Pathology, Adelaide, South Australia, Australia
^e Department of Cardiology, Royal Adelaide Hospital, Adelaide, South Australia, Australia
^f Centre for Nutrition and Gastrointestinal Diseases, University of Adelaide, Adelaide, South Australia, Australia
^g School of Electrical and Electronic Engineering, University of Adelaide, Adelaide, South Australia, Australia

^⁎Requests for reprints should be addressed to Dennis H. Lau, Centre for Heart Rhythm Disorders, Royal Adelaide Hospital, Port Road, Adelaide, SA 5000, AUSTRALIACentre for Heart Rhythm DisordersRoyal Adelaide HospitalPort RoadAdelaideSA5000AUSTRALIA

Plan

Case Report

Discussion

	Funding: This work is supported by Equipment Grants from the Adelaide Medical School, The University of Adelaide (UoA) and the Tom Simpson Trust Fund, Heart Foundation of Australia (HFA) South Australia Division.
	Conflicts of Interest: PH and MB report none. RW is supported by scholarships from the National Health and Medical Research Council of Australia (NHMRC) and the Australian Government Research Training Program. ADE is supported by the HFA. PS is supported by a practitioner fellowship from NHMRC and HFA and reports having served on the advisory board of Biosense-Webster, Medtronic, Abbott, Boston Scientific and CathRx. PS reports lecture and/or consulting fees from Biosense-Webster, Medtronic, Abbott, and Boston Scientific and research funding from Medtronic, Abbott, Boston Scientific, Biotronik and Liva Nova. AP is supported by a University of Adelaide Beacon Research Fellowship. DHL is supported by a Robert J. Craig Lectureship from the University of Adelaide and The Hospital Research Foundation. DHL reports receiving lecture and/or consulting fees from Abott Medical, Bayer, Biotronik, Boehringer Ingelheim, BMS/Pfizer and Medtronic.
	Authorship: All authors had access to the data and a role in writing this manuscript.